For advanced NSCLC without targetable driver mutations, such as epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK), platinum‐doublet chemotherapy has been the standard first‐line treatment for decades, with a median overall survival (OS) of 8–10 months. Here, EGFR is linked to non-small cell lung carcinoma.